Barclays raised the firm’s price target on Baxter (BAX) to $41 from $39 and keeps an Overweight rating on the shares. The firm updated its model to reflect the company’s 2025 guidance and recent commentary.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Tariff delay positive for Mexico-exposed medtech companies, says BofA
- Baxter added to US Conviction List at Goldman Sachs
- Baxter reinstated with a Buy at Goldman Sachs
- Baxter International Poised for Financial Improvement with Strong EPS Growth and Margin Enhancements
- Baxter files automatic mixed securities shelf